

Ziad Bakouny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8094024/publications.pdf>

Version: 2024-02-01

145
papers

5,422
citations

201674

27
h-index

98798

67
g-index

177
all docs

177
docs citations

177
times ranked

9175
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	5.9	9
2	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	6.4	40
3	Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 719-721.	5.4	1
4	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	2
5	COVID-19 vaccination and breakthrough infections in patients with cancer. <i>Annals of Oncology</i> , 2022, 33, 340-346.	1.2	76
6	Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 343-343.	1.6	1
7	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.9	8
8	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022, 40, 281-281.	1.6	1
9	Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. <i>The Lancet Healthy Longevity</i> , 2022, 3, e143-e152.	4.6	16
10	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	5.9	43
11	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	5.0	12
12	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
13	Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 301-306.	1.9	7
14	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4549-4549.	1.6	0
15	Smoking and COVID-19 in patients with cancer: Novel analysis from CCC19 registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18766-e18766.	1.6	0
16	Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16521-e16521.	1.6	0
17	Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16522-e16522.	1.6	0
18	Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6520-6520.	1.6	1

#	ARTICLE	IF	CITATIONS
19	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	29
20	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	12.8	84
21	Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 39-39.	1.6	6
22	Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 274-274.	1.6	8
23	Transcriptional mediators of treatment resistance in lethal prostate cancer. <i>Nature Medicine</i> , 2021, 27, 426-433.	30.7	90
24	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2021, 7, 458.	7.1	177
25	Thrombotic complications with SARS-CoV-2 infection in patients with cancer on high-risk therapies: Data from the COVID-19 and Cancer Consortium (CCC19).. <i>Journal of Clinical Oncology</i> , 2021, 39, e18788-e18788.	1.6	2
26	Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4529-4529.	1.6	0
27	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	16.8	263
28	The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4552-4552.	1.6	0
29	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 773.	7.1	21
30	Lower respiratory tract disease (LRTD) in patients with cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6563-6563.	1.6	0
31	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4583-4583.	1.6	0
32	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	16.8	230
33	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , 2021, 32, 787-800.	1.2	240
34	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	7.1	149
35	Machine Learning and Real-World Data: More than Just Buzzwords. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 811-813.	2.1	4
36	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	3.8	23

#	ARTICLE	IF	CITATIONS
37	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1042-1044.	16.8	23
38	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103463.	4.4	3
39	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. <i>Lung Cancer</i> , 2021, 160, 78-83.	2.0	10
40	Beyond conventional immune-checkpoint inhibition – novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 199-214.	27.6	179
41	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2134330.	5.9	32
42	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. <i>Nature Communications</i> , 2021, 12, 7304.	12.8	17
43	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020, 6, 37-40.	3.1	6
44	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	1.6	109
45	Influence of spino-pelvic and postural alignment parameters on gait kinematics. <i>Gait and Posture</i> , 2020, 76, 318-326.	1.4	18
46	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 464-470.	2.0	18
47	How do skeletal and postural parameters contribute to maintain balance during walking?. <i>Human Movement Science</i> , 2020, 72, 102658.	1.4	5
48	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> , 2020, 38, 769-770.	16.8	54
49	Survey of the Impact of COVID-19 on Oncologists'™ Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020, 6, 1248-1257.	1.8	33
50	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	9.4	108
51	LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). <i>Annals of Oncology</i> , 2020, 31, S1204.	1.2	4
52	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	16.8	26
53	Quelle est la méthode radiographique la plus fiable pour évaluer l'arche plantaire médiale? Application sur une population d'adolescents souffrant d'une scoliose idiopathique. <i>Revue De Chirurgie Orthopedique Et Traumatologique</i> , 2020, 106, 785.	0.0	0
54	IL-8 and cancer prognosis on immunotherapy. <i>Nature Medicine</i> , 2020, 26, 650-651.	30.7	72

#	ARTICLE	IF	CITATIONS
55	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	13.7	1,395
56	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1606.	7.1	79
57	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	30.7	488
58	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020, 26, 1041-1043.	30.7	161
59	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 135, 203-210.	2.8	50
60	What is the most reliable radiographic method to evaluate the longitudinal foot arch? Application in subjects with Adolescent Idiopathic Scoliosis. <i>Orthopaedics and Traumatology: Surgery and Research</i> , 2020, 106, 1263-1268.	2.0	3
61	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020, 127, 118-122.	2.8	24
62	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 615-623.	1.9	44
63	Alterations of 3D acetabular and lower limb parameters in adolescent idiopathic scoliosis. <i>European Spine Journal</i> , 2020, 29, 2010-2017.	2.2	3
64	Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102947.	4.4	4
65	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	3.4	47
66	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
67	TBK1 Activation by VHL Loss in Renal Cell Carcinoma: A Novel HIF-Independent Vulnerability. <i>Cancer Discovery</i> , 2020, 10, 348-350.	9.4	7
68	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	16.8	196
69	Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis. <i>Blood</i> , 2020, 136, 28-30.	1.4	5
70	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5010-5010.	1.6	2
71	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5063-5063.	1.6	5
72	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-43.	1.6	3

#	ARTICLE	IF	CITATIONS
73	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. Journal of Clinical Oncology, 2020, 38, 608-608.	1.6	15
74	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	1.6	3
75	Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. Journal of Clinical Oncology, 2020, 38, 728-728.	1.6	2
76	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2020, 38, 5070-5070.	1.6	0
77	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. Journal of Clinical Oncology, 2020, 38, 5046-5046.	1.6	0
78	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. Journal of Clinical Oncology, 2020, 38, 5077-5077.	1.6	1
79	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 684-684.	1.6	5
80	Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.. Journal of Clinical Oncology, 2020, 38, 698-698.	1.6	2
81	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	1.6	1
82	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. Immunotherapy, 2019, 11, 913-920.	2.0	13
83	Prevalence of HIV and other sexually transmitted infections and their association with sexual practices and substance use among 2238 MSM in Lebanon. Scientific Reports, 2019, 9, 15142.	3.3	16
84	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2019, 30, v396.	1.2	4
85	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	7.0	50
86	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology, 2019, 76, 861-867.	1.9	71
87	Single-institution experience of medical students's bacterial colonization during training. American Journal of Infection Control, 2019, 47, 268-270.	2.3	1
88	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Future Oncology, 2019, 15, 909-923.	2.4	10
89	Second-line Treatments of Advanced Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2019, 53, 251-261.	2.2	19
90	The relationships between bone variables and physical fitness across the BMI spectrum in young adult women. Journal of Bone and Mineral Metabolism, 2019, 37, 520-528.	2.7	10

#	ARTICLE	IF	CITATIONS
91	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. Clinical and Translational Oncology, 2019, 21, 280-288.	2.4	6
92	Factors associated with the time to first palliative care consultation in Lebanese cancer patients. Supportive Care in Cancer, 2019, 27, 1529-1533.	2.2	6
93	Causes of death in older patients with cancer: Experience of a tertiary care center in Lebanon. Journal of Geriatric Oncology, 2019, 10, 365-367.	1.0	0
94	Alterations of treatment-naïve pelvis and thigh muscle morphology in children with cerebral palsy. Journal of Biomechanics, 2019, 82, 178-185.	2.1	8
95	Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn's Disease. Journal of Clinical Gastroenterology, 2019, 53, 409-417.	2.2	17
96	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 103-103.	1.6	5
97	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4514-4514.	1.6	5
98	Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 652-652.	1.6	4
99	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. Journal of Clinical Oncology, 2019, 37, 653-653.	1.6	4
100	Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 66-66.	1.6	0
101	Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 664-664.	1.6	0
102	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 3052-3052.	1.6	1
103	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 4577-4577.	1.6	1
104	Is the apical vertebra the most rotated vertebra in the scoliotic curve?. Journal of Neurosurgery: Spine, 2019, 31, 873-879.	1.7	4
105	Total Parenteral Nutrition in Middle Eastern Cancer Patients at End of Life: Is it Justified?. gulf journal of oncology, The, 2019, 1, 21-25.	0.2	0
106	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. Future Oncology, 2018, 14, 829-835.	2.4	6
107	Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care, 2018, 13, 119-123.	1.4	2
108	Normative spino-pelvic sagittal alignment of Lebanese asymptomatic adults: Comparisons with different ethnicities. Orthopaedics and Traumatology: Surgery and Research, 2018, 104, 557-564.	2.0	15

#	ARTICLE	IF	CITATIONS
109	A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. <i>Immunotherapy</i> , 2018, 10, 657-663.	2.0	14
110	Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference?. <i>Future Oncology</i> , 2018, 14, 891-895.	2.4	5
111	Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in Crohn's disease: The controversy remains. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e16-e18.	1.5	6
112	Is there a role for the platelet-to-lymphocyte ratio in chronic lymphocytic leukemia?. <i>Future Science OA</i> , 2018, 4, FSO344.	1.9	3
113	A network meta-analysis of the frontline immune-checkpoint inhibitor-based regimens in advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, x22.	1.2	0
114	Cervical and postural strategies for maintaining horizontal gaze in asymptomatic adults. <i>European Spine Journal</i> , 2018, 27, 2700-2709.	2.2	22
115	The nephrotoxicity of immune checkpoint inhibitor-based combinations. <i>European Journal of Cancer</i> , 2018, 103, 274-278.	2.8	5
116	P 154 - How do 3D skeletal parameters and demographics determine kinematic adaptation from normal to fast speed gait?. <i>Gait and Posture</i> , 2018, 65, 490-492.	1.4	0
117	Combining acetabular and femoral morphology improves our understanding of the down syndrome hip. <i>Clinical Biomechanics</i> , 2018, 58, 96-102.	1.2	1
118	Are the sagittal cervical radiographic modifiers of the Ames-ISSG classification specific to adult cervical deformity?. <i>Journal of Neurosurgery: Spine</i> , 2018, 29, 483-490.	1.7	18
119	Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. <i>Future Oncology</i> , 2018, 14, 2225-2227.	2.4	0
120	Validity and reliability of different techniques of neck shaft angle measurement. <i>Clinical Radiology</i> , 2018, 73, 984.e1-984.e9.	1.1	9
121	O 068 - The variation of lateral and posterior coverage of the femoral head by the acetabulum during walking influences stability during gait. <i>Gait and Posture</i> , 2018, 65, 139-141.	1.4	0
122	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 60-69.	4.4	20
123	Spinopelvic Alignment in Subjects With Down Syndrome. <i>Clinical Spine Surgery</i> , 2018, 31, E322-E328.	1.3	2
124	Influence of patient axial malpositioning on the trueness and precision of pelvic parameters obtained from 3D reconstructions based on biplanar radiographs. <i>European Radiology</i> , 2017, 27, 1295-1302.	4.5	20
125	Roussouly's sagittal spino-pelvic morphotypes as determinants of gait in asymptomatic adult subjects. <i>Gait and Posture</i> , 2017, 54, 27-33.	1.4	13
126	Influence of patient rotational malpositioning on pelvic parameters assessed on lateral radiographs. <i>Clinical Radiology</i> , 2017, 72, 794.e11-794.e17.	1.1	2

#	ARTICLE	IF	CITATIONS
127	A podoscopic and descriptive study of foot deformities in patients with Down syndrome. Orthopaedics and Traumatology: Surgery and Research, 2017, 103, 123-127.	2.0	12
128	Une Étude descriptive et podoscopique des déformations du pied dans le syndrome de Down. Revue De Chirurgie Orthopedique Et Traumatologique, 2017, 103, 87.	0.0	0
129	O101: How spino-pelvic postural alignment influences gait kinematics?. Gait and Posture, 2017, 57, 177-178.	1.4	2
130	O71: Skeletal and anthropometric determinants of gait balance in asymptomatic adult subjects. Gait and Posture, 2017, 57, 123-124.	1.4	0
131	Axial and frontal plane skeletal hip alignment are crucial for gait in asymptomatic adults. Gait and Posture, 2017, 57, 13-14.	1.4	0
132	Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. Future Oncology, 2017, 13, 2709-2717.	2.4	6
133	The optimal treatment of metastatic hormone-naïve prostate cancer: abiraterone acetate or docetaxel?. Future Oncology, 2017, 13, 2785-2790.	2.4	5
134	Skeletal hip parameters as determinants of gait in asymptomatic adult subjects. Revue De Chirurgie Orthopedique Et Traumatologique, 2017, 103, S47.	0.0	0
135	Alterations in acetabular orientation and hip morphology in subjects with adult spinal deformity. Revue De Chirurgie Orthopedique Et Traumatologique, 2017, 103, S100-S101.	0.0	0
136	What are the strategies for maintaining horizontal gaze in asymptomatic subjects?. Revue De Chirurgie Orthopedique Et Traumatologique, 2017, 103, S103.	0.0	0
137	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. International Journal of Hematologic Oncology, 2017, 6, 105-111.	1.6	4
138	Three-dimensional evaluation of skeletal deformities of the pelvis and lower limbs in ambulant children with cerebral palsy. Gait and Posture, 2016, 49, 102-107.	1.4	18
139	Relationship of sagittal alignment and acetabular orientations as measured in upright position in asymptomatic adults. Revue De Chirurgie Orthopedique Et Traumatologique, 2016, 102, S152.	0.0	0
140	Spino-pelvic coronal and sagittal alignment in Down's syndrome patients. Revue De Chirurgie Orthopedique Et Traumatologique, 2016, 102, S153.	0.0	0
141	How the type of sagittal alignment defined by Roussouly determines the gait of the asymptomatic adult subject. Revue De Chirurgie Orthopedique Et Traumatologique, 2016, 102, S179-S180.	0.0	2
142	Validation of hip joint center localization methods during gait analysis using 3D EOS imaging in typically developing and cerebral palsy children. Gait and Posture, 2016, 48, 30-35.	1.4	28
143	Three-dimensional kinematics of upper limb anatomical movements in asymptomatic adults: Dominant vs. non-dominant. Human Movement Science, 2016, 50, 10-18.	1.4	13
144	A New Approach in the Clinical Decision - Making for Cerebral Palsy Using Three - Dimensional Subject - Specific Musculoskeletal Reconstructions. Journal Medical Libanais, 2016, 64, 152-159.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Normal subjects with different sagittal spino-pelvic morphotypes may walk differently. Gait and Posture, 2015, 42, S30-S31.	1.4	0